Equities Analysts Offer Predictions for McKesson Q3 Earnings

McKesson Corporation (NYSE:MCK) – Equities research analysts at Zacks Research cut their Q3 2026 earnings per share estimates for McKesson in a research report issued to clients and investors on Wednesday, November 26th. Zacks Research analyst Team now expects that the company will post earnings of $9.21 per share for the quarter, down from their prior forecast of $9.68. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson’s Q4 2026 earnings at $11.04 EPS, FY2026 earnings at $38.37 EPS, Q1 2027 earnings at $9.54 EPS, Q2 2027 earnings at $10.00 EPS, Q3 2027 earnings at $10.56 EPS, Q4 2027 earnings at $11.56 EPS, FY2027 earnings at $41.66 EPS, Q1 2028 earnings at $10.09 EPS, Q2 2028 earnings at $10.92 EPS and FY2028 earnings at $49.29 EPS.

A number of other brokerages have also commented on MCK. Robert W. Baird increased their price objective on McKesson from $873.00 to $927.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a report on Tuesday, November 25th. Jefferies Financial Group lifted their price objective on McKesson from $820.00 to $900.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $887.69.

McKesson Price Performance

MCK opened at $856.39 on Monday. The company’s 50 day simple moving average is $810.30 and its 200-day simple moving average is $742.71. McKesson has a one year low of $558.13 and a one year high of $895.58. The stock has a market capitalization of $105.70 billion, a P/E ratio of 34.15, a price-to-earnings-growth ratio of 1.46 and a beta of 0.51.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $9.86 earnings per share for the quarter, beating the consensus estimate of $8.84 by $1.02. McKesson had a net margin of 0.84% and a negative return on equity of 196.66%. The firm had revenue of $103.15 billion during the quarter, compared to analysts’ expectations of $103.80 billion. During the same quarter last year, the company posted $7.07 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 1st will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, December 1st. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 10.21%.

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $861.63, for a total value of $283,476.27. Following the completion of the sale, the chief accounting officer owned 328 shares of the company’s stock, valued at approximately $282,614.64. This represents a 50.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.08% of the company’s stock.

Hedge Funds Weigh In On McKesson

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in McKesson by 2.0% during the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after acquiring an additional 232,286 shares in the last quarter. State Street Corp increased its holdings in shares of McKesson by 0.9% in the third quarter. State Street Corp now owns 5,750,519 shares of the company’s stock worth $4,447,110,000 after acquiring an additional 51,510 shares in the last quarter. Geode Capital Management LLC raised its position in shares of McKesson by 4.1% during the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after purchasing an additional 112,224 shares during the period. Franklin Resources Inc. lifted its holdings in shares of McKesson by 3.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock valued at $2,071,428,000 after purchasing an additional 90,948 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in shares of McKesson by 5.6% in the 3rd quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock valued at $1,850,001,000 after purchasing an additional 126,684 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.